LEXEO THERAPEUTICS INC (LXEO) Stock Earnings & Estimates
USA - NASDAQ:LXEO - US52886X1072 - Common Stock
8.95 USD
-0.14 (-1.54%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 520K | 1.66M 219.23% | 650K -60.84% | -100.00% | 19.38M | 150.64M 677.30% | 384.79M 155.44% | 763.59M 98.44% | 1.31B 71.56% | 1.93B 47.33% | ||||
| EBITDA YoY % growth | -4.59M | -50.63M -1,003.05% | -60.24M -18.98% | -73.44M -12.78% | -102M -55.10% | -104.04M 1.26% | -78.54M 24.51% | -73.44M 6.49% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.59M | -50.64M -1,003.27% | -60.51M -19.49% | -72.634M -13.23% | -109.29M -54.72% | -118.328M -11.63% | -113.79M 3.84% | -119.83M -5.31% | -85.544M 28.61% | 64.919M 175.89% | 322.72M 397.11% | 518.16M 60.56% | 1.005B 93.96% | |
| Operating Margin | -882.69% | -3,050.60% | -9,309.23% | N/A | N/A | N/A | N/A | -618.32% | -56.79% | 16.87% | 42.26% | 39.55% | 52.07% | |
| EPS YoY % growth | N/A | N/A | N/A | -4.12 | -3.18 25.32% | -2.56 16.88% | -2.04 20.27% | -2.24 -9.53% | -1.58 29.52% | -0.10 93.85% | 2.11 2,278.95% | 7.99 278.26% | 15.06 88.51% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.43 45.51% | -0.39 61.05% | -0.48 20.78% | -0.55 -66.14% | -0.54 -27.80% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -19.38M 23.64% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -27.196M 0.68% | -29.875M 11.63% | -28.039M 8.63% | -29.354M -35.60% | -30.221M -11.12% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.33 62.92% | -0.53 | 0.20 | 37.78% |
| Q2 2025 Q2Q % growth | -0.60 6.25% | -0.69 | 0.09 | 13.49% |
| Q1 2025 Q2Q % growth | -0.99 -28.57% | -0.80 | -0.19 | -23.91% |
| Q4 2024 Q2Q % growth | -0.78 8.24% | -0.82 | 0.04 | 5.26% |
| Q3 2024 Q2Q % growth | -0.89 92.80% | -0.69 | -0.20 | -28.59% |
| Q2 2024 Q2Q % growth | -0.64 | -0.71 | 0.07 | 9.25% |
| Q1 2024 Q2Q % growth | -0.77 | -0.78 | 0.01 | 1.64% |
| Q4 2023 Q2Q % growth | -0.85 | -0.74 | -0.11 | -14.55% |
| Q3 2023 Q2Q % growth | -12.36 | -2.65 | -9.71 | -366.42% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 16.87% | 19.2% | 0.4% | 4.92% |
| Revenue | N/A | N/A | N/A | N/A |